Ignite Creation Date:
2024-05-05 @ 6:34 PM
Last Modification Date:
2024-10-26 @ 9:34 AM
Study NCT ID:
NCT00500071
Status:
COMPLETED
Last Update Posted:
2022-03-10
First Post:
2007-07-10
Brief Title:
Dose-Optimization Study Evaluating the Efficacy Safety and Tolerability of Vyvanse Lisdexamfetamine Dimesylate in Children Aged 6-12 Diagnosed With ADHD
Sponsor:
Shire
Organization:
Takeda
Study Overview
Official Title:
A Prospective Open-Label Multi-Center Dose-Optimization Study Evaluating the Efficacy Safety and Tolerability of Vyvanse Lisdexamfetamine Dimesylate 20-70mg in Children Aged 6-12 Diagnosed With ADHD
Status:
COMPLETED
Status Verified Date:
2022-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Assess the efficacy tolerability of Vyvanse when children aged 6-12 years diagnosed with ADHD are dosed to optimal effect
Detailed Description:
Dose-Optimization Study Evaluating the Efficacy Safety and Tolerability of Vyvanse lisdexamfetamine dimesylate in Children aged 6-12 Diagnosed with ADHD
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None